GlassScriptPhysician profile
Vicki L Mcintyre
NPI 1629075643
$68,432.44
in general payments reported to CMS, 2019-2025
26 companies · $9,210 in 2025
The $9,210 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17K · 2022: $14K · 2023: $13K · 2024: $15K · 2025: $9,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Travel and Lodging: $5,000 · Food and Beverage: $4,974 · Consulting Fee: $4,600 · Education: $6.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,850.00 |
| Travel and Lodging | $5,000.48 |
| Food and Beverage | $4,974.17 |
| Consulting Fee | $4,600.00 |
| Education | $6.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $61,567.98 | 2021-2025 | Epclusa, Livdelzi |
| Abbvie INC. | $2,709.79 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $542.80 | 2021-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $491.66 | 2021-2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $462.63 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $389.31 | 2022-2023 | |
| Madrigal Pharmaceuticals | $340.58 | 2024-2025 | Rezdiffra, Resmetirom |
| Mallinckrodt Hospital Products INC. | $292.75 | 2023-2025 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $243.66 | 2025 | |
| Boston Scientific Corporation | $239.62 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $232.81 | 2024-2025 | Iqirvo, Bylvay |
| Intra-Sana Laboratories | $148.87 | 2023-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Eisai INC. | $143.66 | 2021-2023 | |
| Orphalan INC | $122.52 | 2023-2025 | Cuvrior |
| Merck Sharp & Dohme LLC | $103.95 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $102.52 | 2024 | Stelara, Tremfya |
| Histosonics, INC. | $59.15 | 2024 | |
| Exact Sciences Corporation | $46.02 | 2023-2024 | Cologuard Collection Kit |
| Albireo Pharma, INC. | $37.14 | 2023 | Bylvay |
| Genzyme Corporation | $32.90 | 2024 | |
| Travere Therapeutics, INC. | $24.03 | 2023 | Cholbam |
| Eton Pharmaceuticals, INC. | $23.97 | 2025 | Nitisinone, Betaine Anhydrous, Carglumic Acid |
| Alnylam Pharmaceuticals INC. | $20.17 | 2021 | |
| Glaxosmithkline, LLC. | $18.19 | 2022 | |
| Ferring Pharmaceuticals INC. | $17.92 | 2024 | Rebyota |
| Exelixis INC. | $17.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicki Mcintyre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.